'Remarkable' new benefit in HER2+ breast cancer

February 15, 2019 8:04 AM | Anonymous

February 15, 2019, Medscape 

The treatment of HER2-positive, early stage breast cancer has taken "one more step toward personalized medicine and reduced mortality" thanks to the results of the KATHERINE trial, according to Daniel Hayes, MD, a medical oncologist at the University of Michigan Rogel Cancer Center in Ann Arbor. He says the trial is a "game changer" for patients who have residual disease after initial drug treatment and surgery, in an editorial published online in the New England Journal of Medicine. 

Read more.

Powered by Wild Apricot Membership Software